Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

Steven A. Rosenberg; James C. Yang; Douglas J. Schwartzentruber; Patrick Hwu; Francesco M. Marincola; Suzanne L. Topalian; Nicholas P. Restifo; Mark E. Dudley; Susan L. Schwarz; Paul J. Spiess; John R. Wunderlich; Maria R. Parkhurst; Yutaka Kawakami; Claudia A. Seipp; Jan H. Einhorn; Donald E. White

doi:10.1038/nm0398-321

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

Steven A. Rosenberg, James C. Yang, Douglas J. Schwartzentruber, Patrick Hwu, Francesco M. Marincola, Suzanne L. Topalian, Nicholas P. Restifo, Mark E. Dudley, Susan L. Schwarz, Paul J. Spiess, John R. Wunderlich, Maria R. Parkhurst, Yutaka Kawakami, Claudia A. Seipp, Jan H. Einhorn, Donald E. White

Research output: Contribution to journal › Article › peer-review

1659 Scopus citations

Abstract

The cloning of the genes encoding cancer antigens has opened new possibilities for the treatment of patients with cancer. In this study, immunodominant peptides from the gp100 melanoma-associated antigen were identified, and a synthetic peptide, designed to increase binding to HLA-A2 molecules, was used as a cancer vaccine to treat patients with metastatic melanoma. On the basis of immunologic assays, 91% of patients could be successfully immunized with this synthetic peptide, and 13 of 31 patients (42%) receiving the peptide vaccine plus IL-2 had objective cancer responses, and four additional patients had mixed or minor responses. Synthetic peptide vaccines based on the genes encoding cancer antigens hold promise for the development of novel cancer immunotherapies.

Original language	English (US)
Pages (from-to)	321-327
Number of pages	7
Journal	Nature medicine
Volume	4
Issue number	3
DOIs	https://doi.org/10.1038/nm0398-321
State	Published - 1998
Externally published	Yes

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1038/nm0398-321

Cite this

Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H., & White, D. E. (1998). Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature medicine, 4(3), 321-327. https://doi.org/10.1038/nm0398-321

Rosenberg, SA, Yang, JC, Schwartzentruber, DJ, Hwu, P, Marincola, FM, Topalian, SL, Restifo, NP, Dudley, ME, Schwarz, SL, Spiess, PJ, Wunderlich, JR, Parkhurst, MR, Kawakami, Y, Seipp, CA, Einhorn, JH & White, DE 1998, 'Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma', Nature medicine, vol. 4, no. 3, pp. 321-327. https://doi.org/10.1038/nm0398-321

@article{a5e7df9ec3124472b0922337f67ffb6f,

title = "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma",

abstract = "The cloning of the genes encoding cancer antigens has opened new possibilities for the treatment of patients with cancer. In this study, immunodominant peptides from the gp100 melanoma-associated antigen were identified, and a synthetic peptide, designed to increase binding to HLA-A2 molecules, was used as a cancer vaccine to treat patients with metastatic melanoma. On the basis of immunologic assays, 91% of patients could be successfully immunized with this synthetic peptide, and 13 of 31 patients (42%) receiving the peptide vaccine plus IL-2 had objective cancer responses, and four additional patients had mixed or minor responses. Synthetic peptide vaccines based on the genes encoding cancer antigens hold promise for the development of novel cancer immunotherapies.",

author = "Rosenberg, {Steven A.} and Yang, {James C.} and Schwartzentruber, {Douglas J.} and Patrick Hwu and Marincola, {Francesco M.} and Topalian, {Suzanne L.} and Restifo, {Nicholas P.} and Dudley, {Mark E.} and Schwarz, {Susan L.} and Spiess, {Paul J.} and Wunderlich, {John R.} and Parkhurst, {Maria R.} and Yutaka Kawakami and Seipp, {Claudia A.} and Einhorn, {Jan H.} and White, {Donald E.}",

year = "1998",

doi = "10.1038/nm0398-321",

language = "English (US)",

volume = "4",

pages = "321--327",

journal = "Nature medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

AU - Rosenberg, Steven A.

AU - Yang, James C.

AU - Schwartzentruber, Douglas J.

AU - Hwu, Patrick

AU - Marincola, Francesco M.

AU - Topalian, Suzanne L.

AU - Restifo, Nicholas P.

AU - Dudley, Mark E.

AU - Schwarz, Susan L.

AU - Spiess, Paul J.

AU - Wunderlich, John R.

AU - Parkhurst, Maria R.

AU - Kawakami, Yutaka

AU - Seipp, Claudia A.

AU - Einhorn, Jan H.

AU - White, Donald E.

PY - 1998

Y1 - 1998

N2 - The cloning of the genes encoding cancer antigens has opened new possibilities for the treatment of patients with cancer. In this study, immunodominant peptides from the gp100 melanoma-associated antigen were identified, and a synthetic peptide, designed to increase binding to HLA-A2 molecules, was used as a cancer vaccine to treat patients with metastatic melanoma. On the basis of immunologic assays, 91% of patients could be successfully immunized with this synthetic peptide, and 13 of 31 patients (42%) receiving the peptide vaccine plus IL-2 had objective cancer responses, and four additional patients had mixed or minor responses. Synthetic peptide vaccines based on the genes encoding cancer antigens hold promise for the development of novel cancer immunotherapies.

AB - The cloning of the genes encoding cancer antigens has opened new possibilities for the treatment of patients with cancer. In this study, immunodominant peptides from the gp100 melanoma-associated antigen were identified, and a synthetic peptide, designed to increase binding to HLA-A2 molecules, was used as a cancer vaccine to treat patients with metastatic melanoma. On the basis of immunologic assays, 91% of patients could be successfully immunized with this synthetic peptide, and 13 of 31 patients (42%) receiving the peptide vaccine plus IL-2 had objective cancer responses, and four additional patients had mixed or minor responses. Synthetic peptide vaccines based on the genes encoding cancer antigens hold promise for the development of novel cancer immunotherapies.

UR - http://www.scopus.com/inward/record.url?scp=0031890206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031890206&partnerID=8YFLogxK

U2 - 10.1038/nm0398-321

DO - 10.1038/nm0398-321

M3 - Article

C2 - 9500606

AN - SCOPUS:0031890206

SN - 1078-8956

VL - 4

SP - 321

EP - 327

JO - Nature medicine

JF - Nature medicine

IS - 3

ER -

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this